Specific alterations of microRNA transcriptome and global network structure in colorectal carcinoma after cetuximab treatment

Molecular Cancer Therapeutics

Volumn 9, Issue 12, 2010, Pages 3396-3409

  Ragusa, Marco ^a   Majorana, Alessandra ^a   Statello, Luisa ^a   Maugeri, Marco ^a   Salito, Loredana ^a   Barbagallo, Davide ^a   Guglielmino, Maria Rosa ^a   Duro, Laura R ^a   Angelica, Rosario ^a   Caltabiano, Rosario ^b   Biondi, Antonio ^b   Di Vita, Maria ^b   Privitera, Giuseppe ^b   Scalia, Marina ^a   Cappellani, Alessandro ^b   Vasquez, Enrico ^b   Lanzafame, Salvatore ^b   Basile, Francesco ^b   Di Pietro, Cinzia ^a   Purrello, Michele ^a  

^a Unità di BioMedicina Molecolare Genomica e dei Sistemi Complessi   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; MICRORNA; MOLECULAR MARKER; PANITUMUMAB; TRANSCRIPTION FACTOR; TRANSCRIPTOME; UBIQUITIN;

ARTICLE; CANCER CELL CULTURE; COLORECTAL CARCINOMA; CONTROLLED STUDY; DOWN REGULATION; DRUG RESPONSE; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; INTERNALIZATION; PRIORITY JOURNAL; TREATMENT RESPONSE; UPREGULATION; WILD TYPE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BINDING SITES; CACO-2 CELLS; CLUSTER ANALYSIS; COLORECTAL NEOPLASMS; CONSERVED SEQUENCE; DRUG SCREENING ASSAYS, ANTITUMOR; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; GENOME, HUMAN; HUMANS; MICRORNAS; MUTATION; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; TIME FACTORS; TRANSCRIPTION FACTORS;

EID: 78650505164     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-10-0137     Document Type: Article

References (47)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
2. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988;319:525-32.
3. Camps J, Grade M, Nguyen QT, Hormann P, Becker S, Hummon AB, et al. Chromosomal breakpoints in primary colon cancer cluster at sites of structural variants in the genome. Cancer Res 2008;68: 1284-95.
4. Walther A, Johnstone E, Swanton C, Midgley R, Tomlinson I, Kerr D. Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer 2009;9:489-99.
5. Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, Leary RJ, et al. The genomic landscapes of human breast and colorectal cancers. Science 2007;318:1108-13.
6. Chang DZ, Kumar V, Ma Y, Li K, Kopetz S. Individualized therapies in colorectal cancer: KRAS as a marker for response to EGFR-targeted therapy. J Hematol Oncol 2009;2:18.
7. Negrini M, Nicoloso MS, Calin GA. MicroRNAs and cancer-new paradigms in molecular oncology. Curr Opin Cell Biol 2009;21: 470-9.
8. Cummins JM, He Y, Leary RJ, Pagliarini R, Diaz LA Jr, Sjobolm T, et al. The colorectal microRNAome. Proc Natl Acad Sci USA 2006; 103:3687-92.
9. Lanza G, Ferracin M, Gafa R, Veronese A, Spizzo R, Pichiorri F, et al. mRNA/microRNA gene expression profile in microsatellite unstable colorectal cancer. Mol Cancer 2007;6:54.
10. Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N, et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 2008;299: 425-36.
11. Xi Y, Nakajima G, Gavin E, Morris CG, Kudo K, Hayashi K, et al. Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples. RNA 2007;13:1668-74.
12. Ng EK, Chong WW, Jin H, Lam EK, Shin VY, Yu J, et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: A potential marker for colorectal cancer screening. Gut 2009;58: 1375-81.
13. Di Pietro C, Ragusa M, Barbagallo D, Duro LR, Guglielmino MR, Majorana A, et al. The apoptotic machinery as a biological complex system: Analysis of its omics and evolution, identification of candidate genes for fourteen major types of cancer, and experimental validation in CML and neuroblastoma. BMC Med Genomics 2009;2:20.
14. Bandres E, Cubedo E, Agirre X, Cayre A, Le Corre D, Buc E, et al. Identification by real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues. Mol Cancer 2006;5:29.
15. Lièvre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008;26:374-9.
16. Ruike Y, Ichimura A, Tsuchiya S, Shimizu K, Kunimoto R, Okuno Y, et al. Global correlation analysis for micro-RNA and mRNA expression profiles in human cell lines. J Hum Genet 2008;53:515-23.
17. Liang Y, Ridzon D, Wong L, Chen C. Characterization of microRNA expression profiles in normal human tissues. BMC Genomics 2007;8:166.
18. Bardelli A, Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 2010;28: 1254-61.
19. Bertram J, Palfner K, Hiddemann W, Kneba M. Overexpression of ribosomal proteins L4 and L5 and the putative alternative elongation factor PTI-1 in the doxorubicin resistant human colon cancer cell line LoVoDxR. Eur J Cancer 1998;34:731-6.
20. Zhong D, Zhang J, Yang S, Soh UJ, Buschdorf JP, Zhou YT, et al. The SAM domain of the RhoGAP DLC1 binds EF1A1 to regulate cell migration. J Cell Sci 2009;122:414-24.
21. Thornton S, Anand N, Purcell D, Lee J. Not just for housekeeping: Protein initiation and elongation factors in cell growth and tumorigenesis. J Mol Med 2003;81:536-48.
22. Voutsadakis IA. The ubiquitin-proteasome system in colorectal cancer. Biochim Biophys Acta 2008;1782:800-8.
23. Fulda S.Tumor resistance to apoptosis. Int J Cancer 2009;124: 511-5.
24. Damia G, D'Incalci M. Targeting DNA repair as a promising approach in cancer therapy. Eur J Cancer 2007;43:1791-801.
25. Weiner LM, Dhodapkar MV, Ferrone S. Monoclonal antibodies for cancer immunotherapy. Lancet 2009;373:1033-40.
26. Vincenzi B, Schiavon G, Silletta M, Santini D, Tonini G. The biological properties of cetuximab. Crit Rev Oncol Hematol 2008;68: 93-106.
27. Vincenzi B, Zoccoli A, Pantano F, Venditti O, Galluzzo S. Cetuximab: From bench to bedside. Curr Cancer Drug Targets 2010;10:80-95.
28. Zheng T, Wang J, Chen X, Liu L. Role of microRNA in anticancer drug resistance. Int J Cancer 2010;126:2-10.
29. Valeri N, Croce CM, Fabbri M. Pathogenetic and clinical relevance of microRNAs in colorectal cancer. Cancer Genomics Proteomics 2009;6:195-204.
30. Zhang W, Winder T, Ning Y, Pohl A, Yang D, Kahn M, et al. A let-7 microRNA-binding site polymorphism in 30-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy (published online ahead of print July 5, 2010). Ann Oncol. doi: 10.1093/ annonc/mdq315
31. Santarius T, Shipley J, Brewer D, Stratton MR, Cooper CS. A census of amplified and overexpressed human cancer genes. Nat Rev Cancer 2010;10:59-64.
32. Hovanes K, Li TW, Munguia JE, Truong T, Milovanovic T, Lawrence Marsh J, et al. Beta-catenin-sensitive isoforms of lymphoid enhancer factor-1 are selectively expressed in colon cancer. Nat Genet 2001;28:53-7.
33. Kohno K, Uchiumi T, Niina I, Wakasugi T, Igaraski T, Momii y, et al. Transcription factors and drug resistance. Eur J Cancer 2005; 41:2577-86.
34. Wang YP, Li KB. Correlation of expression profiles between micro- RNAs and mRNA targets using NCI-60 data. BMC Genomics 2009;10:218.
35. Gen Y, Yasui K, Zen K, Nakajuma T, Tsuji K, Endo M, et al. A novel amplification target, ARHGAP5, promotes cell spreading and migration by negatively regulating RhoA in Huh-7 hepatocellular carcinoma cells. Cancer Lett 2009;275:27-34.
36. Caspi E, Rosin-Arbesfeld R. A novel functional screen in human cells identifies MOCA as a negative regulator of Wnt signaling. Mol Biol Cell 2008;19:4660-74.
37. Miyasaka T, Morita M, Ito K, Suzuki T, Fukuda H, Takeda S, et al. Interaction of antiproliferative protein Tob with the CCR4-NOT deadenylase complex. Cancer Sci 2008;99:755-61.
38. Majidi M, Gutkind JS, Lichy JH. Deletion of the COOH terminus converts the ST5 p70 protein from an inhibitor of RAS signaling to an activator with transforming activity in NIH-3T3 cells. J Biol Chem 2000;275:6560-5.
39. Debucquoy A, Haustermans K, Daemen A, Aydin S, Libbrecht L, Gevaert O, et al. Molecular response to cetuximab and efficacy of preoperative cetuximab-based chemoradiation in rectal cancer. J Clin Oncol 2009;27:2751-7.
40. Patnaik SK, Kannisto E, Knudsen S, Yendamuri S. Evaluation of microRNA expression profiles that may predict recurrence of localized stage I non-small cell lung cancer after surgical resection. Cancer Res 2010;70:36-45.
41. Chen YT, Kitabayashi N, Zhou XK, Fahey TJ 3rd, Scognamiglio T. MicroRNA analysis as a potential diagnostic tool for papillary thyroid carcinoma. Mod Pathol 2008;21:1139-46.
42. Chou CK, Chen RF, Chou FF, Chang HW, Chen YJ, Lee YF, et al. miR- 146b is highly expressed in adult papillary thyroid carcinomas with high risk features including extrathyroidal invasion and the BRAF (V600E) mutation. Thyroid 2010;20:489-94.
43. Hurst DR, Edmonds MD, Scott GK, Benz CC, Vaidya KS, Welch DR. Breast cancer metastasis suppressor 1 up-regulates miR-146, which suppresses breast cancer metastasis. Cancer Res 2009;69:1279-83.
44. Giubellino A, Burke TR Jr, Bottaro DP. Grb2 signaling in cell motility and cancer. Expert Opin Ther Targets 2008;12:1021-33.
45. MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: Components, mechanisms, and diseases. Dev Cell 2009;17:9-26.
46. Scartozzi M, Bearzi I, Pierantoni C, Mandolesi A, Loupakis F, Zaniboni A, et al. Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy. J Clin Oncol 2007;25:3930-5.
47. Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschi T, Manoharan M, et al. Silencing of microRNAs in vivo with "antagomirs." Nature 2005;438:685-9.